The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.

Say goodbye to the classic ClinicalTrials.gov!

The classic ClinicalTrials.gov website will be retired on June 25, 2024. Please use the modernized ClinicalTrials.gov. For more information, see ClinicalTrials.gov Modernization.

Key Record Dates

ClinicalTrials.gov Identifier:	NCT05216432
Brief Title:	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

First Submitted :	December 20, 2021
First Submitted that Met QC Criteria :	January 18, 2022
First Posted :	January 31, 2022

Last Update Submitted that Met QC Criteria :	November 7, 2023
Last Update Posted :	November 9, 2023

To Top